🔥Telegram İfşa

This beautifully written piece describes exactly what, unfortunately, often happens in the clinic. Worth the read. Alankrita Taneja, MD connection.asco.org/blogs/relapsed…

Thrilled to be included in this amazing group of people. The blog I wrote in 2020 still very much resonates with me and what I hear from others. ASCO #ASCO24 #ascoconnection Nathan A. Pennell MD, PhD, FASCO Stephanie Graff, MD, FACP, FASCO Shikha Jain MD, FACP Ashley Love Sumrall, MD, FACP, FASCO Narjust Florez, MD, FASCO Alankrita Taneja, MD gilberto lopes

On #WorldHumanitarianDay, we raise advocate for civilians around the world who are caught up in conflict and honor #humanitarian workers who provide lifesaving support to those in need. #ActForHumanity Watch as Dr. Taneja and Dr. Hadfield discuss #WHD24! oncdata.com/act-for-humani…

In honor of #InternationalOverdoseAwareness Day, Alankrita Taneja and Matthew Hadfield sat down to discuss, raise #awareness, and #advocate for those who have been affected by an #overdose. #TogetherWeCan #IOAD2024 #EndOverdose Listen along here: oncdata.com/international-…

This!!! vox.com/2017/7/5/15880… Deepti Behl, M.D. Maryam Baqir, MD Alankrita Taneja, MD Payal K. Patel @ruvandhi Arghavan Salles, MD, PhD Allison Betof, MD, PhD

#Myeloma Paper of the Day: Cool paper from Rahul Banerjee, MD, FACP showing analysis of S0777 and S1211 SWOG Cancer Research Network trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS & OS: pubmed.ncbi.nlm.nih.gov/39321347/. #mmsm

Patient with chronic back pain and severe anemia. Diagnosis?

#ASH24 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702. *Omitting 24HRU assessments from IMWG criteria changed <1% of responses and had no impact on PFS prediction at any response depth #mmsm #bmtsm

Here are my Top 5 #ASH24 ASH myeloma abstracts. #ASH24VR Links to the full abstract. My Top 5 are based on new data, clinical impact, & methodology Thread with countdown👇

#Myeloma Paper of the Day: Study of outcomes in frail pts getting bispecifics finds best ORR 80% in frail vs 73% in non-frail group; no significant difference in median PFS (NR vs 11 mos) or OS (37 vs 25 mos); similar rates of all grade CRS & ICANS: pubmed.ncbi.nlm.nih.gov/40315372/. #mmsm

Had great thought provoking discussions at 伊藤佑愛 #myelomarounds #Philadelphia Jefferson Health with Dr Binder and 🌟 fellow Tara

'Less is more' maintenance therapy in #MultipleMyeloma! Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg) Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence Based on Ben Derman 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

My mentee, Chidi, an intern at Jefferson Health Einstein Philadelphia Hospital was awarded the Young Investigator Award at Society of Hematologic Oncology (SOHO) for his work on Multiple Myeloma!! So excited for this rising star! 🌟🌟🌟💫

Excellent - linvo approved for 🇺🇸 pts with myeloma! 👍🏻 Q2W & Q4W built into approval 👎🏻 FDA forced 4 prior lines again From press release: "0.95 month median time to first response." When I was a kid, time to 1st response with #MMsm BCMA bsAbs was always exactly 1.2 mo 😉

This strategy will likely result in increased step-up administration of bispecific antibodies in the community setting ashpublications.org/bloodadvances/…

What is it like to transition from being a #fellow to being an #oncology #attending? Watch as Matthew Hadfield and Alankrita Taneja, MD share their biggest lessons, surprises, and insights from their first year in independent practice! Watch here! youtu.be/Xn6qONCFvcg #hemonc #fellowship

This will change my practice. Have seen too many side effects with q4 weekly dosing. jamanetwork.com/journals/jama/…

Daratumumab is now FDA and EU approved for treatment of high risk smoldering myeloma. It is recommended level 1 by NCCN. My thoughts: In the AQUILA randomized trial, daratumumab: -Prolonged time to active myeloma -Prolonged time to end organ damage -Delayed time to needing

Impact of Duffy genotype on PFS w/ RVd +/- ASCT & continuous R maintenance in Pts w/ NDMM: Updated subgroup analysis of the phase 3 DETERMINATION trial [Nov 3, 2025] Lauren Merz et al. #ASH25 abs25-4186 PID 1033 meetings-api.hematology.org/api/abstract/v… #mmsm #bmtsm #CancerDisparities #globonc